Recent FDA Committee Vote Could Speed Multiple Mye : vimarsa

An FDA committee voted unanimously last month to approve a new clinical endpoint, minimal residual disease, when evaluating proposed drugs to treat multipl

Related Keywords

Miami , Florida , United States , Maryalice Stelter Stevenson , Gerald Marti , C Ola Landgren , Seanm Devlin , National Cancer Institute , National Heart , National Institutes Of Health , Drug Administration , Blood Institute , Memorial Sloan Kettering Cancer Center , University Of Miami Miller School Medicine , Myeloma Research Institute , Sylvester Comprehensive Cancer Center , Miami Miller School , National Institutes , Memorial Sloan Kettering Cancer , Evaluating Minimal Residual Disease ,